Formycon AG (ETR:FYB)
17.66
-0.16 (-0.90%)
At close: Mar 27, 2026
Formycon AG Employees
Formycon AG had 245 employees as of June 30, 2025. The number of employees decreased by 5 or -2.00% since the number was reported on December 31, 2024.
Employees
245
Change
-5
Growth
-2.00%
Revenue / Employee
€192,296
Profits / Employee
€660,688
Market Cap
311.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 245 | -5 | -2.00% | 245 | 0 |
| Dec 31, 2024 | 250 | 12 | 5.04% | 250 | 0 |
| Dec 31, 2023 | 238 | 33 | 16.10% | 238 | 0 |
| Dec 31, 2022 | 205 | 34 | 19.88% | 205 | 0 |
| Dec 31, 2021 | 171 | 40 | 30.53% | 125 | 46 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 178,583 |
| Bayer Aktiengesellschaft | 87,280 |
| Siemens Healthineers AG | 73,800 |
| Merck KGaA | 59,077 |
| MEDICLIN Aktiengesellschaft | 6,974 |
| Redcare Pharmacy NV | 2,163 |
| Stratec SE | 1,420 |
| Medios AG | 999 |
Formycon AG News
- 10 days ago - Formycon Secures Europe Launch Timing For FYB203 After Regeneron, Bayer Settlement - Nasdaq
- 10 days ago - EQS-News: Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer - Wallstreet:Online
- 11 days ago - EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025 - Wallstreet:Online
- 24 days ago - EQS-Adhoc: Formycon AG publishes preliminary figures for the 2025 fiscal year - Wallstreet:Online
- 4 weeks ago - EQS-News: Formycon announces positive clinical data for Keytruda biosimilar candidate FYB206 (pembrolizumab) - Wallstreet:Online
- 6 weeks ago - EQS-News: Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda biosimilar candidate FYB206 across major parts of the Asia-Pacific Region - Wallstreet:Online
- 2 months ago - EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, sell - Wallstreet:Online
- 2 months ago - EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, Verkauf • news - Onvista